Analyst Reco. Neurocrine Biosciences, Inc. Deutsche Boerse AG

Equities

NB3

US64125C1099

Market Closed - Deutsche Boerse AG Other stock markets 02:02:51 2024-06-07 am EDT			5-day change	1st Jan Change
121.6 ^EUR	-0.37%		-1.93%	+2.36%

Jun. 05	Transcript : Neurocrine Biosciences, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 02:30 PM
Jun. 03	Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing	May. 31	MT
UBS Raises Price Target on Neurocrine Biosciences to $193 From $174, Maintains Buy Rating	May. 28	MT
Neurocrine Biosciences Insider Sold Shares Worth $297,860, According to a Recent SEC Filing	May. 21	MT
Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing	May. 16	MT
UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating	May. 02	MT
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $216 From $200, Maintains Outperform Rating	May. 02	MT
Wells Fargo Upgrades Neurocrine Biosciences to Overweight From Equalweight, Price Target is $170	Apr. 24	MT
Morgan Stanley Lifts Price Target on Neurocrine Biosciences to $160 From $150, Sees Upside to Shares Ahead of Mid-Stage Readouts; Overweight Kept	Apr. 08	MT
JPMorgan Adjusts Price Target on Neurocrine Biosciences to $158 From $148, Maintains Overweight Rating	Mar. 20	MT
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $200 From $170, Maintains Outperform Rating	Mar. 13	MT
UBS Adjusts Price Target on Neurocrine Biosciences to $159 From $128, Maintains Buy Rating	Feb. 20	MT
Deutsche Bank Raises Neurocrine Biosciences Price Target to $161 From $160, Maintains Buy Rating	Feb. 08	MT
Citigroup Trims Price Target on Neurocrine Biosciences to $140 From $141, Maintains Neutral Rating	Feb. 08	MT
Mizuho Securities Raises Price Target on Neurocrine Biosciences to $140 From $116, Maintains Neutral Rating	Feb. 08	MT
Wells Fargo Raises Price Target on Neurocrine Biosciences to $140 From $127, Maintains Equalweight Rating	Feb. 08	MT
Wedbush Adjusts Neurocrine Biosciences' Price Target to $147 From $141, Keeps Outperform Rating	Jan. 29	MT
Goldman Sachs Raises Price Target on Neurocrine Biosciences to $153 From $134, Maintains Buy Rating	Jan. 25	MT
Barclays Raises Neurocrine Biosciences' Price Target to $150 From $145, Maintains Overweight Rating	Jan. 23	MT
RBC Raises Price Target on Neurocrine Biosciences to $129 From $121, Keeps Sector Perform Rating	Jan. 03	MT
Stifel Adjusts Price Target on Neurocrine Biosciences to $144 From $141, Maintains Buy Rating	Dec. 18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Neurocrine Biosciences, Inc. Deutsche Boerse AG

Equities

NB3

US64125C1099

Analyst Reco.

Filters